Sigrid Therapeutics Selected to Present Results from STAR Proof of Concept Trial at American Diabetes Association 80[th] Scientific Sessions
Stockholm, Sweden — June 8[th], 2020 — Sigrid Therapeutics (Sigrid) today announced that the Company’s STAR study results have been selected for presentation at the American Diabetes Associations 80[th] Scientific Session on June 12-16, 2020 in Chicago, Ilinois. The STAR study (clinicaltrials.org ID no. NCT03823027) was an open-label, single-arm, multicenter study with the primary objective of demonstrating a reduction in long term blood sugar, as measured by HbA1c, in prediabetics after 12 weeks of treatment. The results of the trial have the potential to impact patient care of